Modeling Schizophrenia in Animals

Animal Models for the Study of Human Disease

Volumn , Issue , 2013, Pages 727-755

  Feifel, David ^a   Shilling, Paul D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; antipsychotics; Brattleboro rat; dopamine; glutamate; latent inhibition; neurodevelopmental; prepulse inhibition; schizophrenia

Indexed keywords

EID: 84902030670     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415894-8.00030-0     Document Type: Chapter

References (285)

1. P.C. Sham, C.J. MacLean and K.S. Kendler (1994 Feb) A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand 89(2), 135-141.
2. H. Hafner, K. Maurer, S. Ruhrmann, A. Bechdolf, J. Klosterkotter, M. Wagner, et al. (2004 Apr) Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci 254(2), 117-128.
3. K.S. Cadenhead (2011 Jul 30) Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res 188(2), 208-216.
4. American Psychiatric Association (2000) The diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association text revision
5. D.A. Lewis and J.A. Lieberman (2000 Nov) Catching up on schizophrenia: natural history and neurobiology. Neuron 28(2), 325-334.
6. N.C. Allen, S. Bagade, M.B. McQueen, J.P. Ioannidis, F.K. Kavvoura, M.J. Khoury, et al. (2008 Jul) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SZGene database. Nat Genet 40(7), 827-834.
7. J. Sebat, D.L. Levy and S.E. McCarthy (2009 Dec) Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet 25(12), 528-535.
8. T. Walsh, J.M. McClellan, S.E. McCarthy, A.M. Addington, S.B. Pierce, G.M. Cooper, et al. (2008 Apr 25) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320(5875), 539-543.
9. C.A. Jones, D.J. Watson and K.C. Fone (2011 Oct) Animal models of schizophrenia. Br J Pharmacol 164(4), 1162-1194.
10. S.B. Powell, X. Zhou and M.A. Geyer (2009 Dec 7) Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204(2), 282-294.
11. D.A. Lewis and P. Levitt (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25 409-432.
12. S.B. Powell (2010) Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci 4 435-481.
13. L. Sideli, A. Mule, D. La Barbera and R.M. Murray (2012 Jun) Do child abuse and maltreatment increase risk of schizophrenia? Psychiatry Investig 9(2), 87-99.
14. K. Yui, K. Goto, S. Ikemoto, T. Ishiguro, B. Angrist, G.E. Duncan, et al. (1999 Nov) Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry 4(6), 512-523.
15. D.F. Hermens, D.I. Lubman, P.B. Ward, S.L. Naismith and I.B. Hickie (2009 Feb 16) Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 190(Suppl. 4), S22-S25.
16. J.W. Young, X. Zhou and M.A. Geyer (2010) Animal models of schizophrenia. Curr Top Behav Neurosci 4 391-433.
17. A. Carlsson (1977 Nov) Does dopamine play a role in schizophrenia? Psychol Med 7(4), 583-597.
18. W. Byne, E. Kemether, L. Jones, V. Haroutunian and K.L. Davis (1999) The neurochemistry of schizophrenia. D.S. Charney, E.J. Nestler, B.S. Bunney (Eds) Neurobiology of mental illness New York: Oxford University Press 236-245.
19. P. Seeman (1992 Dec) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7(4), 261-284.
20. P. Seeman (1995) Dopamine receptors: clinical correlates. F.E. Bloom, D.J. Kupfer (Eds) Psychopharmacology: The fourth generation of progress New York: Raven Press 295-302.
21. G. Szekeres, L. Pavics and Z. Janka (2002 Jul 20) [Investigation of the dopamine dysregulation hypothesis of schizophrenia with neuroimaging techniques]. Ideggyogy Sz 55(7–8), 226-232.
22. O.D. Howes and S. Kapur (2009 May) The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 35(3), 549-562.
23. H. Walter, H. Kammerer, K. Frasch, M. Spitzer and B. Abler (2009 Sep) Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology (Berl) 206(1), 121-132.
24. P. Fusar-Poli, O.D. Howes, P. Allen, M. Broome, I. Valli, M.C. Asselin, et al. (2011 Jan) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16(1), 67-75.
25. U. Klaning, C.B. Pedersen, P.B. Mortensen, K.O. Kyvik and A. Skytthe (2002 Nov 1) A possible association between the genetic predisposition for dizygotic twinning and schizophrenia. Schizophr Res 58(1), 31-35.
26. S. Onstad, I. Skre, S. Torgersen and E. Kringlen (1991 May) Twin concordance for DSM-III-R schizophrenia. Acta Psychiatr Scand 83(5), 395-401.
27. O.D. Howes, J. Kambeitz, E. Kim, D. Stahl, M. Slifstein, A. Abi-Dargham, et al. (2012 Apr 2) The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry
28. J.T. Kantrowitz and D.C. Javitt (2010 Sep 30) N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83(3–4), 108-121.
29. M. Beneyto, A. Abbott, T. Hashimoto and D.A. Lewis (2011 May) Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb Cortex 21(5), 999-1011.
30. W.M. Bullock, K. Cardon, J. Bustillo, R.C. Roberts and N.I. Perrone-Bizzozero (2008 Dec) Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry 165(12), 1594-1603.
31. H. Nasrallah, R. Tandon and M. Keshavan (2011 Dec) Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. Epidemiol Psychiatr Sci 20(4), 317-327.
32. P. Yeganeh-Doost, O. Gruber, P. Falkai and A. Schmitt (2011) The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics (Sao Paulo) 66(Suppl. 1), 71-77.
33. C.A. Tamminga (2003 Nov) The science of antipsychotics: mechanistic insight. CNS Spectr 8(11 Suppl. 2), 5-9.
34. C.A. Tamminga (1997) The promise of new drugs for schizophrenia treatment. Can J Psychiatry 42(3), 265-273. [see comments]
35. W.T. Carpenter and J.I. Koenig (2008 Aug) The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 33(9), 2061-2079.
36. D. Feifel and P. Shilling (2010) Promise and pitfalls of animal models of schizophrenia. Curr Psychiatry Rep 12(4), 327-334.
37. B.K. Lipska, N.R. Swerdlow, M.A. Geyer, G.E. Jaskiw, D.L. Braff and D.R. Weinberger (1995) Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122(1), 35-43.
38. S.B. Powell, N.R. Swerdlow, L.K. Pitcher and M.A. Geyer (2002 Sep) Isolation rearing-induced deficits in prepulse inhibition and locomotor habituation are not potentiated by water deprivation. Physiol Behav 77(1), 55-64.
39. B.A. Ellenbroek, M.A. Geyer and A.R. Cools (1995 Nov) The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J Neurosci 15(11), 7604-7611.
40. R. Hitzemann, B. Malmanger, J. Belknap, P. Darakjian and S. McWeeney (2008 Oct) Short-term selective breeding for high and low prepulse inhibition of the acoustic startle response: pharmacological characterization and QTL mapping in the selected lines. Pharmacol Biochem Behav 90(4), 525-533.
41. K. Schwabe, N. Polikashvili and J.K. Krauss (2009 May) Deficient sensorimotor gating induced by selective breeding in rats is improved by entopeduncular nucleus lesions. Neurobiol Dis 34(2), 351-356.
42. J. Feldon and I. Weiner (1991 Apr 1) The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29(7), 635-646.
43. E.N. Greenblatt, J. Coupet, E. Rauh and V.A. Szucs-Myers (1980 Nov) Is dopamine antagonism a requisite of neuroleptic activity? Arch Int Pharmacodyn Ther 248(1), 105-119.
44. M.L. Wadenberg (2010 Jan) Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des 16(3), 358-370.
45. J.D. Jentsch and R.H. Roth (1999 Mar) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20(3), 201-225.
46. A. Mouri, Y. Noda, T. Enomoto and T. Nabeshima (2007 Jul–Sep) Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 51(2–4), 173-184.
47. M.A. Geyer, K. Krebs-Thomson, D.L. Braff and N.R. Swerdlow (2001 Jul) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156(2–3), 117-154.
48. C.S. Barros, B. Calabrese, P. Chamero, A.J. Roberts, E. Korzus, K. Lloyd, et al. (2009 Mar 17) Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc Natl Acad Sci USA 106(11), 4507-4512.
49. K. Fejgin, S. Safonov, E. Palsson, C. Wass, J.A. Engel, L. Svensson, et al. (2007 Apr) The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 191(2), 377-385.
50. B. Pouzet, M.P. Andersen and S. Hogg (2005 Feb) Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. Psychopharmacology (Berl) 178(1), 9-16.
51. B. Grayson, N.F. Idris and J.C. Neill (2007 Nov 22) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184(1), 31-38.
52. T. Nagai, R. Murai, K. Matsui, H. Kamei, Y. Noda, H. Furukawa, et al. (2009 Jan) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202(1–3), 315-328.
53. S. Snigdha, N. Idris, B. Grayson, M. Shahid and J.C. Neill (2011 Apr) Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) 214(4), 843-853.
54. M. Didriksen, M. Kreilgaard and J. Arnt (2006 Aug 7) Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 542(1–3), 108-115.
55. J.P. Terranova, C. Chabot, M.C. Barnouin, G. Perrault, R. Depoortere, G. Griebel, et al. (2005 Aug) SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) 181(1), 134-144.
56. F. Sams-Dodd (1998) Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci Biobehav Rev 23(2), 287-293.
57. P. Goetghebeur and R. Dias (2009 Jan) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational study. Psychopharmacology (Berl) 202(1–3), 287-293.
58. P.J. Goetghebeur, L. Lerdrup, A. Sylvest and R. Dias (2010 Dec) Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model. Psychopharmacology (Berl) 212(4), 635-642.
59. F. Sams-Dodd (1999) Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 10(1), 59-90.
60. J. He, H. Xu, Y. Yang, D. Rajakumar, X. Li and X.M. Li (2006 Apr 3) The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 168(2), 236-242.
61. F. Sams-Dodd (1998 Apr) A test of the predictive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine. Neuropsychopharmacology 18(4), 293-304.
62. K.Y. Tseng, R.A. Chambers and B.K. Lipska (2009 Dec 7) The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res 204(2), 295-305.
63. N.R. Swerdlow, G.A. Light, M.R. Breier, J.M. Shoemaker, R.L. Saint Marie, A.C. Neary, et al. (2012 May 8) Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev Neurosci
64. R. Tandon, M.S. Keshavan and H.A. Nasrallah (2008 Mar) Schizophrenia, “Just the Facts”: what we know in 2008 part 1: overview. Schizophr Res 100(1–3), 4-19.
65. G. Le Pen and J.L. Moreau (2002 Jul) Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 27(1), 1-11.
66. L.E. Rueter, M.E. Ballard, K.B. Gallagher, A.M. Basso, P. Curzon and K.L. Kohlhaas (2004 Nov) Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl) 176(3–4), 312-319.
67. E.D. Levin and N.C. Christopher (2006 Mar) Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 30(2), 223-229.
68. F. Sams-Dodd, B.K. Lipska and D.R. Weinberger (1997 Aug) Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 132(3), 303-310.
69. M. van den Buuse (2010 Mar) Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 36(2), 246-270.
70. D. Feifel and K. Priebe (2001 Sep 15) Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiatry 50(6), 425-433.
71. J.F. Laycock, I.B. Gartside and J.T. Chapman (1983) A comparison of the learning abilities of Brattleboro rats with hereditary diabetes insipidus and Long-Evans rats using positively reinforced operant conditioning. Prog Brain Res 60 183-187.
72. D. Feifel, S. Mexal, G. Melendez, P.Y. Liu, J.R. Goldenberg and P.D. Shilling (2009 Jul) The Brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology 34(8), 2011-2018.
73. J. de Leon (2003 Feb) Polydipsia—a study in a long-term psychiatric unit. Eur Arch Psychiatry Clin Neurosci 253(1), 37-39.
74. D. Feifel and K. Priebe (2007 Apr) The effects of cross-fostering on inherent sensorimotor gating deficits exhibited by Brattleboro rats. J Gen Psychol 134(2), 173-182.
75. M.G. Feenstra, F.G. Snijdewint, H. Van Galen and G.J. Boer (1990 Mar) Widespread alterations in central noradrenaline, dopamine, and serotonin systems in the Brattleboro rat not related to the local absence of vasopressin. Neurochem Res 15(3), 283-288.
76. R. Dawson Jr., D.R. Wallace and M.J. King (1990) Monoamine and amino acid content in brain regions of Brattleboro rats. Neurochem Res 15(7), 755-761.
77. P.D. Shilling, B. Kinkead, T. Murray, G. Melendez, C.B. Nemeroff and D. Feifel (2006 Dec 1) Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry 60(11), 1278-1281.
78. P. Linkowski, V. Geenen, M. Kerkhofs, J. Mendlewicz and J.J. Legros (1984) Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci 234(3), 162-165.
79. S.O. Frederiksen, R. Ekman, C.G. Gottfries, E. Widerlov and S. Jonsson (1991 Apr) Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 83(4), 273-277.
80. D. Krishnamurthy, L.W. Harris, Y. Levin, T.A. Koutroukides, H. Rahmoune, S. Pietsch, et al. (2012 Jan 17) Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry
81. S. Akbarian and H.S. Huang (2006 Sep) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 52(2), 293-304.
82. D. Feifel, G. Melendez, K. Priebe and P.D. Shilling (2007 Aug 6) The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res 181(2), 278-286.
83. D. Feifel, G. Melendez and P.D. Shilling (2004 Apr) Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 29(4), 731-738.
84. M.A. Geyer and A. Markou (1995) Animal models of psychiatric disorders. F.E. Bloom, D.J. Kupfer (Eds) Psychopharmacology: the fourth generation of progress New York: Raven Press 787-798.
85. O. Blin (1999 Apr) A comparative review of new antipsychotics. Can J Psychiatry 44(3), 235-244.
86. A. Minassian, B.L. Henry, M.A. Geyer, M.P. Paulus, J.W. Young and W. Perry (2010 Jan) The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord 120(1–3), 200-206.
87. D. Feifel (1999) Individual differences in prepulse inhibition of startle as a measure of individual dopamine function. Behav Neurosci 113(5), 1020-1029.
88. D.L. Braff and M.A. Geyer (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47(2), 181-188.
89. A. McGhie and J. Chapman (1961) Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34 102-116.
90. N.R. Swerdlow and M.A. Geyer (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24(2), 285-301.
91. N.R. Swerdlow, D.L. Braff, M.A. Geyer and G.F. Koob (1986) Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry 21(1), 23-33.
92. N.R. Swerdlow, M.A. Geyer and D.L. Braff (2001 Jul) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156(2–3), 194-215.
93. W. Perry and D.L. Braff (1994) Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 151(3), 363-367.
94. K.S. Cadenhead, M.A. Geyer and D.L. Braff (1993) Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. Am J Psychiatry 150(12), 1862-1867.
95. W. Perry, A. Minassian, D. Feifel and D.L. Braff (2001 Sep 15) Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 50(6), 418-424.
96. D.L. Braff (2010) Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci 4 349-371.
97. N.R. Swerdlow, J. Paulsen, D.L. Braff, N. Butters, M.A. Geyer and M.R. Swenson (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 58(2), 192-200.
98. N.R. Swerdlow, C.H. Benbow, S. Zisook, M.A. Geyer and D.L. Braff (1993 Feb 15) A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 33(4), 298-301.
99. F.X. Castellanos, E.J. Fine, D. Kaysen, W.L. Marsh, J.L. Rapoport and M. Hallett (1996) Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 39(1), 33-41.
100. N.R. Swerdlow, M.A. Geyer, J.M. Shoemaker, G.A. Light, D.L. Braff, K.E. Stevens, et al. (2006 Mar) Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology 31(3), 506-515.
101. D.L. Braff, G.A. Light and N.R. Swerdlow (2007 May 15) Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry 61(10), 1204-1207.
102. L.F. Martin and R. Freedman (2007) Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 78 225-246.
103. L.E. Adler, E.M. Cawthra, K.A. Donovan, J.G. Harris, H.T. Nagamoto, A. Olincy, et al. (2005 Feb) Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 162(2), 386-388.
104. L. Su, Y. Cai, L. Wang and S. Shi (2012 Mar) Various effects of antipsychotics on p50 sensory gating in Chinese schizophrenia patients: a meta-analysis. Psychiatr Danub 24(1), 44-50.
105. K.E. Stevens, L.L. Fuller and G.M. Rose (1991 Jul 26) Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating. Brain Res 555(1), 91-98.
106. C.L. Miller, P.C. Bickford, V. Luntz-Leybman, L.E. Adler, G.A. Gerhardt and R. Freedman (1992 Oct) Phencyclidine and auditory sensory gating in the hippocampus of the rat. Neuropharmacology 31(10), 1041-1048.
107. K.E. Stevens, R.G. Johnson and G.M. Rose (1997) Rats reared in social isolation show schizophrenia-like changes in auditory gating. Pharmacol Biochem Behav 58(4), 1031-1036.
108. K.E. Stevens, H. Nagamoto, R.G. Johnson, C.E. Adams and G.M. Rose (1998 Feb) Kainic acid lesions in adult rats as a model of schizophrenia: changes in auditory information processing. Neuroscience 82(3), 701-708.
109. D. Potter, A. Summerfelt, J. Gold and R.W. Buchanan (2006 Oct) Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 32(4), 692-700.
110. P.C. Bickford-Wimer, H. Nagamoto, R. Johnson, L.E. Adler, M. Egan, G.M. Rose, et al. (1990 Jan 15) Auditory sensory gating in hippocampal neurons: a model system in the rat. Biol Psychiatry 27(2), 183-192.
111. J.K. Simosky, R. Freedman and K.E. Stevens (2008 Oct 3) Olanzapine improves deficient sensory inhibition in DBA/2 mice. Brain Res 1233 129-136.
112. J.K. Simosky, K.E. Stevens, L.E. Adler and R. Freedman (2003 Feb) Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl) 165(4), 386-396.
113. M.A. Geyer, N.R. Swerdlow, R.S. Mansbach and D.L. Braff (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25(3), 485-498.
114. T.B. Hammer, B. Oranje, B. Fagerlund, H. Bro and B.Y. Glenthoj (2011 Aug) Stability of prepulse inhibition and habituation of the startle reflex in schizophrenia: a 6-year follow-up study of initially antipsychotic-naive, first-episode schizophrenia patients. Int J Neuropsychopharmacol 14(7), 913-925.
115. W. Perry, A. Minassian, B. Lopez, L. Maron and A. Lincoln (2007 Feb 15) Sensorimotor gating deficits in adults with autism. Biol Psychiatry 61(4), 482-486.
116. S.P. Brooks, T. Pask, L. Jones and S.B. Dunnett (2004 Aug) Behavioural profiles of inbred mouse strains used as transgenic backgrounds. I: motor tests. Genes Brain Behav 3(4), 206-215.
117. R.L. Commissaris, G.M. Harrington, T.J. Baginski and H.J. Altman (1988 Nov) MR/Har and MNRA/Har Maudsley rat strains: differences in acoustic startle habituation. Behav Genet 18(6), 663-669.
118. W. Perry, D. Feifel, A. Minassian, I. Bhattacharjie and D.L. Braff (2002 Aug) Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry 159(8), 1375-1381.
119. R.E. Lubow (1965 Dec) Latent inhibition: effects of frequency of nonreinforced preexposure of the CS. J Comp Physiol Psychol 60(3), 454-457.
120. N.R. Swerdlow, D.L. Braff, H. Hartston, W. Perry and M.A. Geyer (1996 May) Latent inhibition in schizophrenia. Schizophr Res 20(1–2), 91-103.
121. V.P. Bakshi, M.A. Geyer, N. Taaid and N.R. Swerdlow (1995 Dec) A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol 6(8), 801-809.
122. L. Leumann, J. Feldon, F.X. Vollenweider and K. Ludewig (2002 Oct 1) Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry 52(7), 729-739.
123. I. Baruch, D.R. Hemsley and J.A. Gray (1988 Oct) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176(10), 598-606.
124. N.S. Gray, L.S. Pilowsky, J.A. Gray and R.W. Kerwin (1995 Sep) Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17(1), 95-107.
125. C. Rascle, O. Mazas, G. Vaiva, M. Tournant, O. Raybois, M. Goudemand, et al. (2001 Sep 1) Clinical features of latent inhibition in schizophrenia. Schizophr Res 51(2–3), 149-161.
126. R.E. Lubow, R. Dressler and O. Kaplan (1999 Jul) The effects of target and distractor familiarity on visual search in de novo Parkinson's disease patients: latent inhibition and novel pop-out. Neuropsychology 13(3), 415-423.
127. N.R. Swerdlow, H.J. Hartston and P.L. Hartman (1999 Feb 15) Enhanced visual latent inhibition in obsessive-compulsive disorder. Biol Psychiatry 45(4), 482-488.
128. I. Weiner, E. Shadach, R. Tarrasch, R. Kidron and J. Feldon (1996 Nov 1) The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 40(9), 834-843.
129. A. Simonyi, P. Serfozo, K.E. Parker, A.K. Ramsey and T.R. Schachtman (2009 Oct) Metabotropic glutamate receptor 5 in conditioned taste aversion learning. Neurobiol Learn Mem 92(3), 460-463.
130. I. Weiner, R.E. Lubow and J. Feldon (1988 Aug) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30(4), 871-878.
131. H. Russig, C.A. Murphy and J. Feldon (2002 Jun) Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26(6), 765-777.
132. J.C. Thornton, S. Dawe, C. Lee, C. Capstick, P.J. Corr, P. Cotter, et al. (1996 Sep) Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology (Berl) 127(2), 164-173.
133. S.E. Smith, J. Li, K. Garbett, K. Mirnics and P.H. Patterson (2007 Oct 3) Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27(40), 10695-10702.
134. J.H. Williams, N.A. Wellman, D.P. Geaney, P.J. Cowen, J. Feldon and J.N. Rawlins (1996 Dec 1) Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biol Psychiatry 40(11), 1135-1143.
135. I. Bethus, R. Muscat and G. Goodall (2006 Jun) Dopamine manipulations limited to preexposure are sufficient to modulate latent inhibition. Behav Neurosci 120(3), 554-562.
136. P.C. Moser, J.M. Hitchcock, S. Lister and P.M. Moran (2000 Sep) The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Brain Res Rev 33(2–3), 275-307.
137. L.H. Conti, A.A. Palmer, J.J. Vanella and M.P. Printz (2001 May) Latent inhibition and conditioning in rat strains which show differential prepulse inhibition. Behav Genet 31(3), 325-333.
138. T.J. Gould and J.M. Wehner (1999 Dec) Genetic influences on latent inhibition. Behav Neurosci 113(6), 1291-1296.
139. P.J. Harrison and A.J. Law (2006 Jul 15) Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60(2), 132-140.
140. Y.J. Chen, M.A. Johnson, M.D. Lieberman, R.E. Goodchild, S. Schobel, N. Lewandowski, et al. (2008 Jul 2) Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci 28(27), 6872-6883.
141. H. Stefansson, E. Sigurdsson, V. Steinthorsdottir, S. Bjornsdottir, T. Sigmundsson, S. Ghosh, et al. (2002 Oct) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71(4), 877-892.
142. C.M. O'Tuathaigh, A.M. O'Connor, G.J. O'Sullivan, D. Lai, R. Harvey, D.T. Croke, et al. (2008 Feb 15) Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous “knockout” of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 32(2), 462-466.
143. M.S. Golub, S.L. Germann and K.C. Lloyd (2004 Aug 12) Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav Brain Res 153(1), 159-170.
144. K. Roy, J.C. Murtie, B.F. El-Khodor, N. Edgar, S.P. Sardi, B.M. Hooks, et al. (2007 May 8) Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci USA 104(19), 8131-8136.
145. H. Jaaro-Peled (2009) Gene models of schizophrenia: DISC1 mouse models. Prog Brain Res 179 75-86.
146. T.V. Lipina, M. Niwa, H. Jaaro-Peled, P.J. Fletcher, P. Seeman, A. Sawa, et al. (2010 Oct) Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav 9(7), 777-789.
147. S.J. Clapcote, T.V. Lipina, J.K. Millar, S. Mackie, S. Christie, F. Ogawa, et al. (2007 May 3) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54(3), 387-402.
148. M. Niwa, A. Kamiya, R. Murai, K. Kubo, A.J. Gruber, K. Tomita, et al. (2010 Feb 25) Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 65(4), 480-489.
149. T. Hikida, H. Jaaro-Peled, S. Seshadri, K. Oishi, C. Hookway, S. Kong, et al. (2007 Sep 4) Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 104(36), 14501-14506.
150. S. Shen, B. Lang, C. Nakamoto, F. Zhang, J. Pu, S.L. Kuan, et al. (2008 Oct 22) Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J Neurosci 28(43), 10893-10904.
151. H. Koike, P.A. Arguello, M. Kvajo, M. Karayiorgou and J.A. Gogos (2006 Mar 7) Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc Natl Acad Sci USA 103(10), 3693-3697.
152. K.H. Karlsgodt, K. Robleto, H. Trantham-Davidson, C. Jairl, T.D. Cannon, A. Lavin, et al. (2011 Jan 1) Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 69(1), 28-34.
153. S.K. Bhardwaj, M. Baharnoori, B. Sharif-Askari, A. Kamath, S. Williams and L.K. Srivastava (2009 Feb 11) Behavioral characterization of dysbindin-1 deficient sandy mice. Behav Brain Res 197(2), 435-441.
154. K. Takao, K. Toyama, K. Nakanishi, S. Hattori, H. Takamura, M. Takeda, et al. (2008) Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol Brain 1 11.
155. Y.Q. Feng, Z.Y. Zhou, X. He, H. Wang, X.L. Guo, C.J. Hao, et al. (2008 Dec) Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr Res 106(2–3), 218-228.
156. S. Hattori, T. Murotani, S. Matsuzaki, T. Ishizuka, N. Kumamoto, M. Takeda, et al. (2008 Aug 22) Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 373(2), 298-302.
157. T. Murotani, T. Ishizuka, S. Hattori, R. Hashimoto, S. Matsuzaki and A. Yamatodani (2007 Jun 21) High dopamine turnover in the brains of Sandy mice. Neurosci Lett 421(1), 47-51.
158. A.W. Cassidy, S.K. Mulvany, M.N. Pangalos, K.J. Murphy and C.M. Regan (2010 Mar 17) Developmental emergence of reelin deficits in the prefrontal cortex of Wistar rats reared in social isolation. Neuroscience 166(2), 377-385.
159. E. Costa, J. Davis, C. Pesold, P. Tueting and A. Guidotti (2002 Feb) The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr Opin Pharmacol 2(1), 56-62.
160. A.M. Barr, K.N. Fish, A. Markou and W.G. Honer (2008 May) Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins. Eur J Neurosci 27(10), 2568-2574.
161. N.D. Woodward, S.E. Purdon, H.Y. Meltzer and D.H. Zald (2005 Sep) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8(3), 457-472.
162. J.J. Hagan and D.N. Jones (2005 Oct) Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 31(4), 830-853.
163. J.D. Jentsch and L.A. Anzivino (2004 Aug) A low dose of the alpha2 agonist clonidine ameliorates the visual attention and spatial working memory deficits produced by phencyclidine administration to rats. Psychopharmacology (Berl) 175(1), 76-83.
164. W. Marrs, J. Kuperman, T. Avedian, R.H. Roth and J.D. Jentsch (2005 Aug) Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacology 30(8), 1500-1510.
165. A. Egerton, L. Reid, C.E. McKerchar, B.J. Morris and J.A. Pratt (2005 Apr) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl) 179(1), 77-84.
166. P. Willner (1997 Nov) The dopamine hypothesis of schizophrenia: current status, future prospects. Int Clin Psychopharmacol 12(6), 297-308.
167. D. Luchins (1975) The dopamine hypothesis of schizophrenia. A critical analysis. Neuropsychobiology 1(6), 365-378.
168. N.R. Swerdlow, D.L. Braff, N. Taaid and M.A. Geyer (1994 Feb) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51(2), 139-154.
169. A. Menesses (2011) Effects of d-amphetamine on short- and long-term memory in spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rats. Behav Brain Res 216(1), 472-476.
170. N.R. Swerdlow, G.B. Varty and M.A. Geyer (1998) Discrepant findings of clozapine effects on prepulse inhibition of startle: is it the route or the rat? Neuropsychopharmacology 18(1), 50-56.
171. J.C. Ong, S.A. Brody, C.H. Large and M.A. Geyer (2005 Dec) An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther 315(3), 1163-1171.
172. R. Frau, M. Orru, M. Fa, A. Casti, M. Manunta, N. Fais, et al. (2007 Feb) Effects of topiramate on the prepulse inhibition of the acoustic startle in rats. Neuropsychopharmacology 32(2), 320-331.
173. Z.A. Martinez, J. Oostwegel, M.A. Geyer, G.D. Ellison and N.R. Swerdlow (2000 Nov) “Early” and “late” effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits. Neuropsychopharmacology 23(5), 517-527.
174. M.P. Andersen and B. Pouzet (2001 Jul) Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology (Berl) 156(2–3), 291-304.
175. D. Feifel, K. Macdonald, A. Nguyen, P. Cobb, H. Warlan, B. Galangue, et al. (2010 Oct 1) Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 68(7), 678-680.
176. C.A. Pedersen, C.M. Gibson, S.W. Rau, K. Salimi, K.L. Smedley, R.L. Casey, et al. (2011 Oct) Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res 132(1), 50-53.
177. D.S. Segal, M.A. Geyer and M.A. Schuckit (1981) Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol 5 95-129.
178. D.S. Segal and R. Kuczenski (1999) Escalating dose–binge stimulant exposure: relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses. Psychopharmacology (Berl) 142 182-192.
179. M.J. Kreek, S.D. Schlussman, B. Reed, Y. Zhang, D.A. Nielsen, O. Levran, et al. (2009) Bidirectional translational research: progress in understanding addictive diseases. Neuropharmacology 56(Suppl. 1), 32-43.
180. D.S. Segal and R. Kuczenski (1997 Apr 1) An escalating dose “binge” model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17(7), 2551-2566.
181. P.W. Kalivas and P. Duffy (1993 Jan) Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 13(1), 266-275.
182. P.W. Kalivas and P. Duffy (1993 Jan) Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J Neurosci 13(1), 276-284.
183. R. Kuczenski and D.S. Segal (1999 Feb) Sensitization of amphetamine-induced stereotyped behaviors during the acute response. J Pharmacol Exp Ther 288(2), 699-709.
184. D.S. Segal and R. Kuczenski (2006 May) Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. Neuropsychopharmacology 31(5), 941-955.
185. D.S. Segal and R. Kuczenski (1992 Apr 17) Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res 577(2), 351-355.
186. R.E. Featherstone, S. Kapur and P.J. Fletcher (2007 Nov 15) The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31(8), 1556-1571.
187. T. Abekawa, K. Ito, S. Nakagawa, Y. Nakato and T. Koyama (2008 Apr) Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. Schizophr Res 101(1–3), 84-94.
188. M.A. Geyer and B. Moghaddam (2002) Animal models relevant to schizophrenia disorders. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds) Neuropsychopharmacology: the fifth generation of progress Nashville, TN: American College of Neuropsychopharmacology 689-701.
189. G. Tsai and J.T. Coyle (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42 165-179.
190. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, et al. (1994 Mar) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3), 199-214.
191. C.A. Tamminga, H.H. Holcomb, X.M. Gao and A.C. Lahti (1995) Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 10(Suppl. 3(4)), 29-37.
192. J.T. Coyle, G. Tsai and D. Goff (2003 Nov) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003 318-327.
193. L.S. Pilowsky, R.A. Bressan, J.M. Stone, K. Erlandsson, R.S. Mulligan, J.H. Krystal, et al. (2006 Feb) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11(2), 118-119.
194. D.C. Javitt (2010) Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 47(1), 4-16.
195. R.S. Mansbach and M.A. Geyer (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2(4), 299-308.
196. I. Gaisler-Salomon and I. Weiner (2003 Apr) Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berl) 166(4), 333-342.
197. S. Beraki, A. Kuzmin, F. Tai and S.O. Ogren (2008 Jul) Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol. Eur Neuropsychopharmacol 18(7), 486-497.
198. M. Baviera, R.W. Invernizzi and M. Carli (2008 Feb) Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. Psychopharmacology (Berl) 196(2), 269-280.
199. D. Wang, Y. Noda, Y. Zhou, A. Nitta, H. Furukawa and T. Nabeshima (2007 Sep) Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission. Neuropharmacology 53(3), 379-389.
200. D. Feifel and K. Priebe (1999) The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating. Psychopharmacology 146(2), 175-179.
201. D. Feifel and T. Reza (1999) Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 141(1), 93-98.
202. D. Feifel (2012 Jan) Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology 37(1), 304-305.
203. Z.A. Martinez, G.D. Ellison, M.A. Geyer and N.R. Swerdlow (1999) Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 21(1), 28-39.
204. K. Schwabe, J. Brosda, N. Wegener and M. Koch (2005 Feb) Clozapine enhances disruption of prepulse inhibition after sub-chronic dizocilpine- or phencyclidine-treatment in Wistar rats. Pharmacol Biochem Behav 80(2), 213-219.
205. M. Li, E. He and N. Volf (2011 Jun) Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment. Pharmacol Biochem Behav 98(4), 559-569.
206. F. Sams-Dodd (1997 Jun) Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8(2–3), 196-215.
207. P.S. Goldman-Rakic (1994) Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6(4), 348-357.
208. D.R. Weinberger (1987 Jul) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44(7), 660-669.
209. M.A. Geyer, L.S. Wilkinson, T. Humby and T.W. Robbins (1993) Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry 34(6), 361-372.
210. G.B. Varty and G.A. Higgins (1995) Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology 122(1), 15-26.
211. M.J. Millan and M. Brocco (2008 May–Jun) Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138. Therapie 63(3), 187-229.
212. N. Li, X. Wu and L. Li (2007 Mar) Chronic administration of clozapine alleviates reversal-learning impairment in isolation-reared rats. Behav Pharmacol 18(2), 135-145.
213. V.P. Bakshi, N.R. Swerdlow, D.L. Braff and M.A. Geyer (1998) Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine. Biol Psychiatry 43(6), 436-445.
214. J. Cilia, C. Reavill, J.J. Hagan and D.N. Jones (2001 Jul) Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats. Psychopharmacology (Berl) 156(2–3), 327-337.
215. H. Moore, J.D. Jentsch, M. Ghajarnia, M.A. Geyer and A.A. Grace (2006 Aug 1) A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 60(3), 253-264.
216. S. Penschuck, P. Flagstad, M. Didriksen, M. Leist and A.T. Michael-Titus (2006 Jan) Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci 23(1), 279-284.
217. D.J. Lodge and A.A. Grace (2009 Dec 7) Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 204(2), 306-312.
218. G. Le Pen, R. Gourevitch, F. Hazane, C. Hoareau, T.M. Jay and M.O. Krebs (2006 Dec 1) Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat. Neuroscience 143(2), 395-405.
219. E. Hradetzky, T.M. Sanderson, T.M. Tsang, J.L. Sherwood, S.M. Fitzjohn, V. Lakics, et al. (2012 Jan) The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus. Neuropsychopharmacology 37(2), 364-377.
220. H. Jaaro-Peled, Y. Ayhan, M.V. Pletnikov and A. Sawa (2010 Mar) Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr Bull 36(2), 301-313.
221. A.B. Whitworth, M. Honeder, C. Kremser, G. Kemmler, S. Felber, A. Hausmann, et al. (1998 May 25) Hippocampal volume reduction in male schizophrenic patients. Schizophr Res 31(2–3), 73-81.
222. B.K. Lipska, G.E. Jaskiw, S. Chrapusta, F. Karoum and D.R. Weinberger (1992 Jul 10) Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res 585(1–2), 1-6.
223. B.K. Lipska, G.E. Jaskiw and D.R. Weinberger (1993 Aug) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9(1), 67-75.
224. B.K. Lipska and D.R. Weinberger (1993 Oct 15) Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Brain Res Dev Brain Res 75(2), 213-222.
225. B.K. Lipska and D.R. Weinberger (1994 May) Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 10(3), 199-205.
226. B.K. Lipska and D.R. Weinberger (2002 Aug–Sep) A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox Res 4(5–6), 469-475.
227. B.K. Lipska and D.R. Weinberger (2000 Sep) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23(3), 223-239.
228. R.M. Rodriguiz, R. Chu, M.G. Caron and W.C. Wetsel (2004 Jan 5) Aberrant responses in social interaction of dopamine transporter knockout mice. Behav Brain Res 148(1–2), 185-198.
229. R. Mazzoncini, M. Zoli, S. Tosato, A. Lasalvia and M. Ruggeri (2009) Can the role of genetic factors in schizophrenia be enlightened by studies of candidate gene mutant mice behaviour? World J Biol Psychiatry 10(4 Pt 3), 778-797.
230. M. Yamashita, S. Fukushima, H.W. Shen, F.S. Hall, G.R. Uhl, Y. Numachi, et al. (2006 Oct) Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31(10), 2132-2139.
231. S.A. Brody, F. Conquet and M.A. Geyer (2004 Mar) Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl) 172(2), 187-195.
232. S.A. Brody, S.C. Dulawa, F. Conquet and M.A. Geyer (2004 Jan) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9(1), 35-41.
233. G.G. Kinney, M. Burno, U.C. Campbell, L.M. Hernandez, D. Rodriguez, L.J. Bristow, et al. (2003 Jul) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306(1), 116-123.
234. L. Gray, M. van den Buuse, E. Scarr, B. Dean and A.J. Hannan (2009 Feb) Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 12(1), 45-60.
235. R.S. Devon, S. Anderson, P.W. Teague, P. Burgess, T.M. Kipari, C.A. Semple, et al. (2001 Jun) Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet 11(2), 71-78.
236. J.K. Millar, S. Christie, S. Anderson, D. Lawson, D. Hsiao-Wei Loh, R.S. Devon, et al. (2001 Mar) Genomic structure and localisation within a linkage hotspot of Disrupted in Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol Psychiatry 6(2), 173-178.
237. G. Silberberg, A. Darvasi, R. Pinkas-Kramarski and R. Navon (2006 Mar 5) The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet 141B(2), 142-148.
238. M.L. Chen, S.Y. Chen, C.H. Huang and C.H. Chen (2002) Identification of a single nucleotide polymorphism at the 5′ promoter region of human reelin gene and association study with schizophrenia. Mol Psychiatry 7(5), 447-448.
239. J.N. Crawley, J.K. Belknap, A. Collins, J.C. Crabbe, W. Frankel, N. Henderson, et al. (1997) Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132(2), 107-124.
240. W.L. Chang, M.A. Geyer, M.R. Buell, M. Weber and N.R. Swerdlow (2010 Mar) The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behav Pharmacol 21(2), 135-143.
241. T. Lipina, V. Labrie, I. Weiner and J. Roder (2005 Apr) Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) 179(1), 54-67.
242. A.M. Ouagazzal, F. Jenck and J.L. Moreau (2001 Jul) Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology (Berl) 156(2–3), 273-283.
243. D.G. Flood, E. Zuvich, M.J. Marino and M. Gasior (2011 Feb 8) Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse. Psychopharmacology (Berl)
244. K.E. Browman, V.A. Komater, P. Curzon, L.E. Rueter, A.A. Hancock, M.W. Decker, et al. (2004 Aug 12) Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan. Behav Brain Res 153(1), 69-76.
245. M. Zhang, M.E. Ballard, K.L. Kohlhaas, K.E. Browman, A.L. Jongen-Relo, L.V. Unger, et al. (2006 Jul) Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 31(7), 1382-1392.
246. B. Olivier, C. Leahy, T. Mullen, R. Paylor, V.E. Groppi, Z. Sarnyai, et al. (2001 Jul) The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology (Berl) 156(2–3), 284-290.
247. P. Singer, J. Feldon and B.K. Yee (2009 Nov) Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice. Psychopharmacology (Berl) 206(4), 677-698.
248. A.A. Palmer, S.C. Dulawa, A.A. Mottiwala, L.H. Conti, M.A. Geyer and M.P. Printz (2000) Prepulse startle deficit in the Brown Norway Rat: a potential genetic model. Behav Neurosci 11(2), 374-388.
249. L.H. Conti, J.E. Costill, S. Flynn and J.E. Tayler (2005 Aug) Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and by rat strain. Behav Neurosci 119(4), 1052-1060.
250. D. Feifel, P.D. Shilling and G. Melendez (2011 Apr) Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behav Neurosci 125(2), 268-272.
251. D. Feifel, P.D. Shilling and A.M. Belcher (2012 May) The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol 22(5), 374-378.
252. K. Schwabe, F. Freudenberg and M. Koch (2007 Sep) Selective breeding of reduced sensorimotor gating in Wistar rats. Behav Genet 37(5), 706-712.
253. M. Hadamitzky, S. Harich, M. Koch and K. Schwabe (2007) Deficient prepulse inhibition induced by selective breeding of rats can be restored by the dopamine D2 antagonist haloperidol. Behav Brain Res 177(2), 364-367.
254. S.D. Birkett and B.T. Pickering (1988) The vasopressin precursor in the Brattleboro (di/di) rat. Int J Pept Protein Res 32(6), 565-572.
255. H. Valtin and H.A. Schroeder (1964) Familial hypothalamic diabetes insipidus in rats (Brattleboro strain). Am J Physiol 206 425-430.
256. N. Bouby, C. Hassler and L. Bankir (1999) Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 65(10), 991-1004.
257. A. Hurbin, L. Boissin-Agasse, H. Orcel, A. Rabie, N. Joux, M.G. Desarmenien, et al. (1998 Nov) The V1a and V1b, but not V2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology 139(11), 4701-4707.
258. A. Tahara, J. Tsukada, Y. Tomura, K. Wada, T. Kusayama, N. Ishii, et al. (2000) Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells. Br J Pharmacol 129(1), 131-139.
259. B. Bohus and D. de Wied (1998) The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Prog Brain Res 119 555-573.
260. V. Reghunandanan, R. Reghunandanan and K.K. Mahajan (1998) Arginine vasopressin as a neurotransmitter in brain. Indian J Exp Biol 36(7), 635-643.
261. A.R. Williams, R.J. Carey and M. Miller (1985) Altered emotionality of the vasopressin-deficient Brattleboro rat. Peptides 6(Suppl. 1), 69-76.
262. M. Engelmann and R. Landgraf (1994 Jan) Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol Behav 55(1), 145-149.
263. J.D. Jentsch, P.A. Arguello and L.A. Anzivino (2003 Sep) Null mutation of the arginine-vasopressin gene in rats slows attentional engagement and facilitates response accuracy in a lateralized reaction time task. Neuropsychopharmacology 28(9), 1597-1605.
264. M.V. Seeman (2009 Fall) The changing role of mother of the mentally ill: from schizophrenogenic mother to multigenerational caregiver. Psychiatry 72(3), 284-294.
265. J. Neill (1990 Oct) Whatever became of the schizophrenogenic mother? Am J Psychother 44(4), 499-505.
266. C. Sobin, K. Kiley-Brabeck and M. Karayiorgou (2005 Jun) Lower prepulse inhibition in children with the 22q11 deletion syndrome. Am J Psychiatry 162(6), 1090-1099.
267. N. Egashira, K. Mishima, K. Iwasaki, R. Oishi and M. Fujiwara (2009 Jan) New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions. J Pharmacol Sci 109(1), 44-49.
268. J.C. Schank (2009 Jan 30) Early locomotor and social effects in vasopressin deficient neonatal rats. Behav Brain Res 197(1), 166-177.
269. R. Bevan Jones, A. Thapar, G. Lewis and S. Zammit (2012 Mar) The association between early autistic traits and psychotic experiences in adolescence. Schizophr Res 135(1–3), 164-169.
270. A.L. Pelletier and V.A. Mittal (2012 May) An autism dimension for schizophrenia in the next diagnostic and statistical manual? Schizophr Res 137(1–3), 269-270.
271. M. Mlynarik, D. Zelena, G. Bagdy, G.B. Makara and D. Jezova (2007 Mar) Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav 51(3), 395-405.
272. J.J. Legros and M. Ansseau (1992) Neurohypophyseal peptides and psychopathology. Prog Brain Res 93 455-460. discussion 61
273. I. Elman, S. Lukas, S.E. Shoaf, D. Rott, C. Adler and A. Breier (2003 Sep) Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. J Psychopharmacol 17(3), 317-323.
274. T. Kishimoto, M. Hirai, H. Ohsawa, M. Terada, I. Matsuoka and G. Ikawa (1989) Manners of arginine vasopressin secretion in schizophrenic patients—with reference to the mechanism of water intoxication. Jpn J Psychiatry Neurol 43(2), 161-169.
275. J.J. Legros, C. Gazzotti, T. Carvelli, P. Franchimont, M. Timsit-Berthier, R. von Frenckell, et al. (1992 Nov) Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology 17(6), 611-617.
276. A.R. Williams, R.J. Carey and M. Miller (1983 Sep–Oct) Behavioral differences between vasopressin-deficient (Brattleboro) and normal Long-Evans rats. Peptides 4(5), 711-716.
277. D.W. Rowntree (1973 Jul 21) Significance of metabolic disorders in schizophrenia. Lancet 2(7821), 151.
278. J. de Leon, C. Verghese, J.I. Tracy, R.C. Josiassen and G.M. Simpson (1994 Mar 15) Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biol Psychiatry 35(6), 408-419.
279. J. Cilia, J.E. Gartlon, C. Shilliam, L.A. Dawson, S.H. Moore and D.N. Jones (2010 Mar) Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. J Psychopharmacol 24(3), 407-419.
280. M.S. Keshavan, R. Tandon, N.N. Boutros and H.A. Nasrallah (2008 Dec) Schizophrenia, “Just the Facts”: what we know in 2008: part 3: neurobiology. Schizophr Res 106(2–3), 89-107.
281. S. Akbarian, J.J. Kim, S.G. Potkin, J.O. Hagman, A. Tafazzoli, W.E. Bunney Jr., et al. (1995 Apr) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52(4), 258-266.
282. D.W. Volk, M.C. Austin, J.N. Pierri, A.R. Sampson and D.A. Lewis (2000 Mar) Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57(3), 237-245.
283. G.J. Boer, C.M. Van Rheenen-Verberg and H.B. Uylings (1982) Impaired brain development of the diabetes insipidus Brattleboro rat. Brain Res 255(4), 557-575.
284. S. Aarde and J.D. Jentsch (2004) Heterozygosity for the Brattleboro allele (null mutation of the vasopressin gene) is associated with poor spatial working memory. Soc Neurosci 35 911-912. Abstracts
285. W. Perry, R.K. Heaton, E. Potterat, T. Roebuck, A. Minassian and D.L. Braff (2001) Working memory in schizophrenia: transient “online” storage versus executive functioning. Schizophr Bull 27(1), 157-176.